Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Yasuyoshi Sato"'
Autor:
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Publikováno v:
Endocrine Journal, Vol 71, Iss 4, Pp 363-371 (2024)
Proteinuria has been described as a major on-target adverse event of lenvatinib, although its long-term impact on renal function and clinical outcomes remains unclear. We conducted a retrospective observational study to assess renal function and prog
Externí odkaz:
https://doaj.org/article/bf554091c30445589560813f649e4f63
Autor:
Hibiki Udagawa, Shunji Takahashi, Motohiro Hirao, Makoto Tahara, Satoru Iwasa, Yasuyoshi Sato, Takuya Hamakawa, Kohei Shitara, Hidehito Horinouchi, Keisho Chin, Norikazu Masuda, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai, Kan Yonemori
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1269-1278 (2023)
Abstract Background In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. Methods This open‐label, Phase 1 study enrolled Japanese
Externí odkaz:
https://doaj.org/article/73b26d485732490b8b8d2a682fc73707
Autor:
Noriyuki Saito, Yasuyoshi Sato, Hiroyuki Abe, Ikuo Wada, Yukari Kobayashi, Koji Nagaoka, Yoshihiro Kushihara, Tetsuo Ushiku, Yasuyuki Seto, Kazuhiro Kakimi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Understanding the tumor microenvironment (TME) and anti-tumor immune responses in gastric cancer are required for precision immune-oncology. Taking advantage of next-generation sequencing technology, the feasibility and reliability of transc
Externí odkaz:
https://doaj.org/article/f8cbbf03b9be468da664682c89d6beea
Autor:
Akihiro Ohmoto, Kenji Nakano, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Naomi Hayashi, Hirotaka Suto, Shohei Udagawa, Ryosuke Oki, Yasuyoshi Sato, Mayu Yunokawa, Makiko Ono, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Junichi Tomomatsu, Shunji Takahashi
Publikováno v:
PLoS ONE, Vol 18, Iss 3 (2023)
Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was 1 year). The ORR in the 49 evaluable patients was 8%, and the median PFS
Externí odkaz:
https://doaj.org/article/1ad98d3f83ec4a80b58fa31dacaacb84
Autor:
Noriyuki Saito, Yukari Kobayashi, Koji Nagaoka, Yoshihiro Kushihara, Yasuyoshi Sato, Ikuo Wada, Kazuhiro Kakimi, Yasuyuki Seto
Publikováno v:
Biochemistry and Biophysics Reports, Vol 28, Iss , Pp 101167- (2021)
An in-depth understanding of the tumor microenvironment (TME) is required for the development of improved combination immunotherapies for gastric cancer. Recently, we classified these cancers into four main types defined by their immunological attrib
Externí odkaz:
https://doaj.org/article/5083fbf3126d4e1a8af51c48ba6dc19f
Autor:
Yasuyoshi Sato, Ikuo Wada, Kosuke Odaira, Akihiro Hosoi, Yukari Kobayashi, Koji Nagaoka, Takahiro Karasaki, Hirokazu Matsushita, Koichi Yagi, Hiroharu Yamashita, Masashi Fujita, Shuichi Watanabe, Takashi Kamatani, Fuyuki Miya, Junichi Mineno, Hidewaki Nakagawa, Tatsuhiko Tsunoda, Shunji Takahashi, Yasuyuki Seto, Kazuhiro Kakimi
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 10, Pp n/a-n/a (2020)
Abstract Objectives A better understanding of antitumor immunity will help predict the prognosis of gastric cancer patients and tailor the appropriate therapies in each patient. Therefore, we propose a novel immunological classification of gastric ca
Externí odkaz:
https://doaj.org/article/e1cf166d3dc44c398cf2964ef041a912
Autor:
Kohei Shitara, Motohiro Hirao, Satoru Iwasa, Takashi Oshima, Yoshito Komatsu, Akihito Kawazoe, Yasuyoshi Sato, Takuya Hamakawa, Kan Yonemori, Nozomu Machida, Satoshi Yuki, Takuya Suzuki, Shiori Okumura, Takao Takase, Taro Semba, Bob Zimmermann, Angela Teng, Kensei Yamaguchi
Publikováno v:
Clinical Cancer Research. 29:1460-1467
Purpose: In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer. Patients and Methods: Patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c999c58e50a1ca66014a30cf3efc9e76
https://doi.org/10.1158/1078-0432.ccr-22-3027
https://doi.org/10.1158/1078-0432.ccr-22-3027
Autor:
Kensei Yamaguchi, Angela Teng, Bob Zimmermann, Taro Semba, Takao Takase, Shiori Okumura, Takuya Suzuki, Satoshi Yuki, Nozomu Machida, Kan Yonemori, Takuya Hamakawa, Yasuyoshi Sato, Akihito Kawazoe, Yoshito Komatsu, Takashi Oshima, Satoru Iwasa, Motohiro Hirao, Kohei Shitara
Supplementary Figure S5 shows pharmacodynamic changes in biomarkers over time (A) and changes by best overall response (B) in all study 114 cohorts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78bd7682d8d53423d4f89170c3f78d51
https://doi.org/10.1158/1078-0432.22632916
https://doi.org/10.1158/1078-0432.22632916
Autor:
Kensei Yamaguchi, Angela Teng, Bob Zimmermann, Taro Semba, Takao Takase, Shiori Okumura, Takuya Suzuki, Satoshi Yuki, Nozomu Machida, Kan Yonemori, Takuya Hamakawa, Yasuyoshi Sato, Akihito Kawazoe, Yoshito Komatsu, Takashi Oshima, Satoru Iwasa, Motohiro Hirao, Kohei Shitara
Supplementary Table S3 provides a summary of infusion-related reactions during cycle 1, per premedication.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21725ab94435e1bd90949809f249532b
https://doi.org/10.1158/1078-0432.22632907
https://doi.org/10.1158/1078-0432.22632907
Autor:
Kensei Yamaguchi, Angela Teng, Bob Zimmermann, Taro Semba, Takao Takase, Shiori Okumura, Takuya Suzuki, Satoshi Yuki, Nozomu Machida, Kan Yonemori, Takuya Hamakawa, Yasuyoshi Sato, Akihito Kawazoe, Yoshito Komatsu, Takashi Oshima, Satoru Iwasa, Motohiro Hirao, Kohei Shitara
Purpose:In the dose-expansion part of this open-label, phase I study, we explored the efficacy and safety of E7389-LF (liposomal formulation of eribulin) in Japanese patients with advanced gastric cancer.Patients and Methods:Patients with advanced ga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::187f10eea1211a710572f3a4586b8d22
https://doi.org/10.1158/1078-0432.c.6533081.v1
https://doi.org/10.1158/1078-0432.c.6533081.v1